Results

Total Results: 1,848 records

Showing results for "disorder".

1301. An Ethical Framework for N-of-1 Trials: Clinical Care, Quality Improvement, or Human Subjects Research? (Chapter 2) | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/n-1-trials/research-2014-3
      August 01, 2019 - Examples Case 1 The parents of an 8-year old girl diagnosed with attention deficit/hyperactivity disorder … Like Research Protocol Jan 08, 2025 Management of Attention-Deficit/Hyperactivity Disorder

1302. Therapies for Clinically Localized Prostate Cancer | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/prostate-cancer-therapies/protocol
      March 01, 2020 - Review Research Protocol Jan 08, 2025 Diagnosis of Attention-Deficit/Hyperactivity Disorder … Review Research Protocol Jan 08, 2025 Management of Attention-Deficit/Hyperactivity Disorder

1303. AHRQ EPC Program Research Gaps Summary: Women's Health (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/product/pdf/research-gaps-womens-health-22.pdf
      April 01, 2022 - • Develop and validate instruments for accurately predicting risk of opioid use disorder or misuse

1304. Screening and Diagnosing Gestational Diabetes Mellitus | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/gestational-diabetes-screening-diagnosis/research
      December 01, 2019 - Skip to main content An official website of the Department of Health & Human Services Careers Contact Us Español FAQs Effective Health Care Program Powered by the Evidence-based Practice Centers …

1305. Management of Infertility | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/infertility/research
      March 01, 2022 - Skip to main content An official website of the Department of Health & Human Services Careers Contact Us Español FAQs Effective Health Care Program Powered by the Evidence-based Practice Centers …

1306. Linking Dental Services to Treatment Outcomes for Diabetes: A Rapid Response Review | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/treatment-outcomes-diabetes/rapid-research
      October 01, 2024 - Type II diabetes mellitus is a highly prevalent metabolic disorder characterized by the loss of ability

1307. AHRQ Slide Template
      effectivehealthcare-admin.ahrq.gov/sites/default/files/wysiwyg/pdf/epc-pain-management-grand-rounds-slides.pptx
      March 01, 2022 - outcomes (i.e., pain, overall function, adverse effects (e.g., dizziness, nausea, sedation, cannabis use disorder

1308. DEMENTIA INCLUDING ALZHEIMER'S #04 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/dementia-horizon-scan-high-impact-1412.pdf
      February 01, 2015 - The National Institute on Aging defines AD as a progressive, irreversible disorder, marked by degraded

1309. Fractional Exhaled Nitric Oxide Clinical Utility in Asthma Management | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/asthma-nitric-oxide/research-protocol
      June 01, 2021 - Background and Objectives for the Systematic Review Asthma is a chronic inflammatory disorder

1310. Systematic Review of Intermittent Inhaled Corticosteroids and of Long-acting Muscarinic Antagonists for Asthma | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/asthma-pharmacologic-treatment/research-protocol
      April 01, 2021 - Background and Objectives for the Systematic Review Asthma is a chronic inflammatory disorder of the … (MHRA) ‡ approved by the European Medicines Agency (EMA) COPD=chronic obstructive pulmonary disorder

1311. The Effectiveness of Indoor Allergen Reduction and the Role of Bronchial Thermoplasty in the Management of Asthma | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/asthma-nonpharmacologic-treatment/research-protocol
      April 01, 2021 - Background and Objectives for the Systematic Review Asthma is a chronic inflammatory disorder

1312. Layout 1 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/sleep-apnea_executive.pdf
      July 01, 2011 - Layout 1 Backgrounda Obstructive sleep apnea (OSA) is a relatively common disorder in the United States … Ongoing debate surrounds what type and level of respiratory abnormality should be used to define the disorder

1313. Evidence-based Practice Center Systematic Review Protocol (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/tinnitus_research-protocol.pdf
      February 22, 2012 - Prevalence of otologic complaints in patients with temporomandibular disorder. … Tinnitus, dizziness, and nonotologic otalgia improvement through temporomandibular disorder therapy

1314. Research White Paper Patient- or Participant-Generated Registries Addendum Registries for Evaluating Patient Outcomes Third Edition (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/wysiwyg/patient-participant-generated-registries-guide-3rd-ed-addendum-white-paper.pdf
      February 01, 2018 - pediatricians whose son suffered from Hutchison-Gilford progeria syndrome, which is a very rare genetic disorder … hundred participants would be needed, requiring several years’ worth of data collection for such a rare disorder

1315. Evaluation and Treatment of Tinnitus: A Comparative Effectiveness Review | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/tinnitus/research-protocol
      December 01, 2019 - Prevalence of otologic complaints in patients with temporomandibular disorder. … Tinnitus, dizziness, and nonotologic otalgia improvement through temporomandibular disorder therapy.

1316. Hypertension-Pulmonary-Arterial Research-Protocol (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/hypertension-pulmonary-arterial_research-protocol.pdf
      January 30, 2013 - suspected PAH and asymptomatic patients at high risk for PAH (e.g., patients with a collagen vascular disorder … hypertension (PAH) or asymptomatic patients at high risk for PAH (e.g., patients with a collagen vascular disorder … neither (1) a condition associated with a high risk of undiagnosed PAH (e.g., a collagen vascular disorder

1317. #14 SUBSTANCE ABUSE (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/substance-abuse-horizon-scan-high-impact-1406.pdf
      January 01, 2020 - Off-label baclofen for treatment of alcohol use disorder No high-impact potential at this time Discussion … off-label use of baclofen, a gamma aminobutyric acid (GABA) B-receptor agonist, for treating alcohol use disorder … little-to-no superiority over competing approved and off-label medications for treating alcohol use disorder

1318. Disposition of Comments_Technical Brief No. 45: Long COVID Models of Care (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/long-covid-disposition-comments.pdf
      January 01, 2022 - may be unique, often presenting as a new phenotype in patients with a history of a primary headache disorder … I have severe COVID brain fog and vision disturbance, severe pain, movement disorder, scattered thinking

1319. Transparency of Reporting Requirements: Tympanostomy Tubes (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/transparency-tympanostomy_research-protocol.pdf
      September 02, 2016 - Transparency of Reporting Requirements: Tympanostomy Tubes Source: www.effectivehealthcare.ahrq.gov Published online: September 2, 2016 Evidence-based Practice Center Methodology Repor t Protocol Project Title: Transparency of Repor ting Requirements Repor t Topic: Tympanostomy Tubes I. Background Info…

1320. Diabetes-Drugs-Utilization Research (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/diabetes-drugs-utilization_research.pdf
      March 01, 2011 - Utilization of antidiabetic drugs among Medicare beneficiaries with diabetes, 2006-2009 Diabetes Treatment Data Points #9 Biguanides (i.e., metformin) were the most commonly used antidiabetic drug class among Medicare beneficiaries from 2006 to 2009, followed by sulfonylureas, insulins, and thiazolidinediones…